Travere Therapeutics, Inc. - 8-K Filing
Travere Therapeutics completed a $525 million offering of 0.50% Convertible Senior Notes due 2032, including a $50 million over-allotment exercised by underwriters on May 11, 2026. The notes are senior unsecured obligations with an initial conversion price of approximately $64.90 per share and will mature in May 2032. (Items: 1.01 Entry into a Material Definitive Agreement, 8.01 below, which includes $50, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, 3.02 Unregistered Sale of Equity Securities)
Tickers: $TVTX